RxSight, Inc.

For the period ended Dec 31, 2025. Filed Feb 25, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 25, 2026

RXST$4.90+0.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

	Year Ended December 31,
	2025	2024	2023
Operating Activities:
Net loss	$(38,944)	$(27,455)	$(48,608)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,266	3,575	4,078
Provision for bad debts	32	34	—
Amortization of debt issuance costs and premium	—	—	287
Loss on extinguishment of debt	—	—	1,769
Amortization of discount on short-term investments	(8,517)	(8,977)	(6,122)
Stock-based compensation	31,612	24,635	15,746
Provision for excess and obsolete inventory	1,932	404	164
Change in operating assets and liabilities:
Accounts receivable	6,655	(9,803)	(9,325)
Inventories	(11,482)	(4,993)	(2,749)
Prepaid and other assets	1,183	(1,181)	(397)
Accounts payable	627	946	1,250
Accrued expenses and other liabilities	(1,875)	5,869	2,314
Net cash used in operating activities	(15,511)	(16,946)	(41,593)
Investing Activities:
Purchase of property and equipment	(3,830)	(5,440)	(4,814)
Maturity of short-term investments	260,000	243,000	255,000
Purchases of short-term investments	(239,281)	(336,871)	(272,315)
Net cash provided by (used in) investing activities	16,889	(99,311)	(22,129)
Financing Activities:
Proceeds from term loan	—	—	20,000
Repayment of term loan	—	—	(60,000)
Proceeds from issuance of common stock from public offering	—	108,100	54,050
Proceeds from issuance of common stock from at-the-market offerings	—	—	42,434
Proceeds from issuance of common stock	3,951	20,816	9,473
Payments for employee taxes related to stock compensation	(2,062)	(4,768)	(1,423)
Principal payments on finance lease liabilities	(26)	(61)	(153)
Payments of deferred offering costs	—	(768)	(622)
Payments of debt issuance costs	—	—	(2,235)
Net cash provided by financing activities	1,863	123,319	61,524
Effect of foreign exchange rate on cash, cash equivalents and restricted cash	3	(9)	6
Net increase (decrease) in cash, cash equivalents and restricted cash	3,243	7,053	(2,192)
Cash, cash equivalents and restricted cash - beginning of period	17,456	10,403	12,595
Cash, cash equivalents and restricted cash - end of period	$20,699	$17,456	$10,403
Supplemental disclosure of cash flow information:
Operating cash flows from operating leases	2,627	2,154	2,216
Cash paid for income taxes	58	24	8
Cash paid for interest on term loan	—	—	3,464
Non-cash investing and financing activities:
Right-of-use assets obtained in exchange for lease obligations:
Operating lease	29	10,016	46
Lease obligations recorded for right-of-use assets:
Operating lease	29	10,016	46
Acquisition of property and equipment included in accounts payable and accrued expenses and other current liabilities	421	545	282
Deferred offering and financing costs included in accounts payable and accrued liabilities	—	—	145
Reclassification of deferred financing costs	—	768	1,390

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.